These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16084028)

  • 1. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
    Berger R
    Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
    [No Abstract]   [Full Text] [Related]  

  • 2. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.
    McClure R; Mai M; Lasho T
    Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039
    [No Abstract]   [Full Text] [Related]  

  • 3. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
    Greiner TC
    Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
    [No Abstract]   [Full Text] [Related]  

  • 4. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
    James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
    Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A unifying mutation in chronic myeloproliferative disorders.
    Goldman JM
    N Engl J Med; 2005 Apr; 352(17):1744-6. PubMed ID: 15858182
    [No Abstract]   [Full Text] [Related]  

  • 6. JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders.
    Bellosillo B; Besses C; Florensa L; Solé F; Serrano S
    Leukemia; 2006 Apr; 20(4):736-7. PubMed ID: 16453004
    [No Abstract]   [Full Text] [Related]  

  • 7. Inconsistencies in the association between the JAK2(V617F) mutation and PRV-1 over-expression among the chronic myeloproliferative diseases.
    Vannucchi AM; Guglielmelli P; Antonioli E; Mappa S; Pancrazzi A; Bogani C; Ponziani V; Bosi A
    Br J Haematol; 2006 Mar; 132(5):652-4; author reply 654. PubMed ID: 16445842
    [No Abstract]   [Full Text] [Related]  

  • 8. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The V617F JAK2 mutation and the myeloproliferative disorders.
    Percy MJ; McMullin MF
    Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
    McLornan D; Percy M; McMullin MF
    Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
    [No Abstract]   [Full Text] [Related]  

  • 11. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients.
    Vizmanos JL; Ormazábal C; Larráyoz MJ; Cross NC; Calasanz MJ
    Leukemia; 2006 Mar; 20(3):534-5. PubMed ID: 16408096
    [No Abstract]   [Full Text] [Related]  

  • 12. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.
    Rossi D; Deambrogi C; Capello D; Cerri M; Lunghi M; Parvis G; Saglio G; Gaidano G; Cilloni D
    Br J Haematol; 2006 Oct; 135(2):267-8. PubMed ID: 16956348
    [No Abstract]   [Full Text] [Related]  

  • 13. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
    Bousquet M; Brousset P
    Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders.
    Pesu M; O'Shea J; Hennighausen L; Silvennoinen O
    Mol Interv; 2005 Aug; 5(4):211-5. PubMed ID: 16123535
    [No Abstract]   [Full Text] [Related]  

  • 15. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
    Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
    Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAKing up hematopoietic proliferation.
    Shannon K; Van Etten RA
    Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
    Ma W; Kantarjian H; Verstovsek S; Jilani I; Gorre M; Giles F; Cortes J; O'Brien S; Keating M; Albitar M
    Br J Haematol; 2006 Aug; 134(3):341-3. PubMed ID: 16787500
    [No Abstract]   [Full Text] [Related]  

  • 18. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
    Spivak JL; Moliterno AR; Silver RT
    N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
    Lasho TL; Mesa R; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Sep; 130(5):797-9. PubMed ID: 16115143
    [No Abstract]   [Full Text] [Related]  

  • 20. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
    Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.